**Specifications Table**TableSubject areaClinical laboratoryMore specific subject area*Biomarkers for clinical chemistry associated with diabetes*Type of data*Tables*How data was acquired*Capture from literature data for 1,5-AG concentration and methodology. Comparison reference interval data was obtained with enzymatic colorimetric assay (Glycomark) measured in automate system (LabMax 400, Labtest, Brazil)*Data format*Analyzed*Experimental factors*Blood samples (serum or plasma EDTA) measured with different methodologies*Experimental features*Compilation, calculations, analysis (descriptive statistics) and comparison of literature data*Data source location*Federal University of Parana, Curitiba, Brazil.*Data accessibility*Data is in published papers and in this article.*Related research articleM. Welter, K.C. Boritza, M.I. Anghebem-Oliveira, R. Henneberg, A.B. Hauser, F.G.M. Rego, G. Picheth, Reference intervals for serum 1,5-anhydroglucitol in children, adolescents, adults, and pregnant women, CCA (2018) [@bib1].

**Value of the data**•Data will facilitate the comparison of 1,5-AG in different studies.•The data showed the correlation among 1,5-AG and relevant parameters associated with diabetes.•The data provide comparison between 1,5-AG reference interval in different ethnicities, ages, gender and methodologies.•These data provide information to researchers and clinical laboratory professionals to improve the 1,5-AG diagnostic use.

1. Data {#s0005}
=======

In this article, we provide complementary data (urea, total protein and lipid profile) of the studied groups ([Table 1](#t0005){ref-type="table"}), correlation analysis ([Table 2](#t0010){ref-type="table"}) and comparisons from the literature for serum 1,5-anhydroglycitol (1,5-AG) concentration, to our study. We proposed a reference interval ([Tables 3](#t0015){ref-type="table"} and [4](#t0020){ref-type="table"}) for this biomarker in children, adolescent, adults and pregnant women [@bib2].Table 1Complementary laboratory characteristic of studied groups.Table 1**ParametersChildren n = 580Adolescents n = 496Adults n = 922Pregnant women n = 305**Sex (M/F)242/338192/304460/462--Urea, mmol/L3.8 (3.1--4.5)3.8 (3.2--4.3)4.3 (3.5--5.3)3.4 (2.8--4.3)Total Protein, g/L81 (74--89)78 (71--85)71 (67--74)69 (64--74)Cholesterol, mmol/L4.1 (3.6--4.6)3.9 (3.4--4.4)4.4 (4.0--5.4)5.2 (4.1--6.2)HDL-c, mmol/L1.4 (1.2--1.6)1.3 (1.0--1.5)1.4 (1.1--1.5)1.2 (1.0--1.6)LDL-c, mmol/L2.1 (1.7--2.5)2.1 (1.7--2.6)2.5 (2.0--3.1)3.0 (2.5--4.1)Triglycerides, mmol/L1.1 (0.8--1.5)0.8 (0.6--1.1)1.4 (1.0--2.0)1.3 (1.0--2.0)[^1][^2][^3]Table 2Significative (*P* \< 0.05) Spearman rank order correlation of 1,5 anhydroglucitol with glycemia, HbA1c, age, body mass index (BMI) and creatinine.Table 2**GroupsSex1,5-AG correlation (R)GlycemiaHbA1cAgeBMICreatinine**Children (0--14 y)MaleNSNS0.133NSNSFemaleNS0.128NSNS0.163Adolescents (14--18 y)MaleNS0.2210.1530.151NSFemaleNSNS0.221NSNSAdults (≥18 y)MaleNSNS−0.144NSNSFemaleNSNS−0.102NSNSCombining allNSNS−0.310−0.1870.112Pregnant women**Gestation weeks**n = 110\<23 weeksNS--NSNSNSn = 10624--28 weeksNS--NSNSNSn = 5229--32 weeksNS--NSNS0.402n = 37\>32NS--NSNSNSCombining pregnant0.095--−0.155NSNS[^4][^5]Table 3Serum 1,5-anhydroglucitol reference intervals and concentrations in different healthy populations.Table 3**1,5-AG, µmol/LStudies/Methodology[Sex]{.ul}MaleFemaleSubjectsR.I.nR.I.n**Children and adolescents (5--18 years)(92--298)432(84--278)642Our study [@bib2] Enzymatic colorimetric GlycoMark^TM^US adolescents (12--18 years)(95--178)6(140--172)5[@bib3] Enzymatic colorimetric GlycoMark^TM^\[88--212\]\[120--180\]150 ± 31150 ± 15(95--178)\[102--198\]150 ± 24US young158 ± 4082143 ± 3754[@bib4] Enzymatic colorimetric GlycoMark^TM^(54--227)(10--29 years)(63--271)\[69--217\]\[78--238\]Total (*n* = 136) 151 ± 39 (54--271); \[73--229\](\<18 years)158 ± 35 \[88--228\](\>18 years) 137 ± 42 \[53--221\]Adults (19--79 years)(80--260)460(62--241)462Our study [@bib2] Enzymatic colorimetric GlycoMark^TM^Finland adults (25--50 years)93 mean2977 mean110[@bib5] Gas chromatography (GC)81 mean; 10--146 range (*n* = 139)US adults (18--39 years)(61--207)224(37--195)224[@bib6] Enzymatic colorimetric GlycoMark^TM^US adults (18--39 years)(52−178)875(50−166)924[@bib7]Australian adults (40 ± 13 years)125 ± 41 (*n* = 95)[@bib8] Enzymatic colorimetric GlycoMark^TM^\[43--207\]German adults157 ± 44 (*n* = 116)[@bib9] Liquid chromatography--mass Spectrometric (LC--MS)\[69--245\]Chinese Mauritians144 ± 51 (*n *= 82)[@bib10] Enzymatic pyranose oxidase\[42--246\](98--195)Chinese adults (22--80 years)182 ± 39159 ± 52[@bib11] Enzymatic pyranose oxidase\[104--260\]\[55--263\]92--294 (*n *= 57)Chinese adults \>20 and \<40 years \>50 years176 ± 46 \[84--268\]82116 ± 35 \[46--186\]185[@bib12] Liquid chromatography negative ion electrospray tandem mass spectrometry (LC--MS/MS)166 ± 67 \[32--300\]9122 ± 41 \[40--204\]14Chinese adults(83.1--240.7)[@bib13] Enzymatic161.9 ± 40.2\[81.5--242.3\] (*n *= 120)Chinese adults (22--78 years)190 ± 54254160 ± 49322[@bib14] Enzymatic colorimetric GlycoMark^TM^\[82--298\]\[62--258\](69--278)\[67--279\]173 ± 53Chinese adults (20--79 years)(107--367)226(79--306)232[@bib15] Enzymatic Medical system, Ningbo, China226.3 ± 60.7175.2 ± 55.8\[104.9--347.7\]\[63.6--286.8\]Japanese (18--81 years)132 ± 36 (*n* = 45)[@bib16] Gas--liquid chromatography (GLC)\[60--204\]Japanese (mean 47 years)145 ± 44 (*n *= 229)[@bib17] Gas--liquid chromatography (GLC)\[57--233\]Japanese (27--68 years)(114--215)[@bib18] Gas--liquid chromatography (GLC)158 ± 38\[82--234\]Japanese adults (23--76 years)159.8 ± 9.8 (*n* = 20)[@bib19] Enzymatic Nippon--Kayaku\[140--179\]Japanese adults (30--79 years)140 ± 56991122 ± 431104[@bib20] Enzymatic Kyowa Medex Co.\[28--252\]\[36--208\]Japanese adults137.1 ± 8.2181120.6 ± 39203[@bib21] Enzymatic Lana Nippon--Kayaku\[120.7--153.5\]231\[42.6--198.6\]519(50.5 ± 9.7 y)(54.1 ± 10.3)124.3 ± 45.1115.1 ± 40.2\[34.1--214.5\]\[34.7--195.5\](74.5 ± 5.8 y)(75.3 ± 6.7 y)[^6][^7]Table 4Serum 1,5-anhydroglucitol reference intervals and concentrations in pregnancy in different populations.Table 4**Pregnant1,5-AG, μmol/L R.I.nStudies/Methodology**Pregnant Women \<23 weeks of gestation(56--298)110Our study [@bib2] Enzymatic colorimetric GlycoMark^TM^Pregnant Women \>24 weeks of gestation(33--181)195Our study [@bib2] Enzymatic colorimetric GlycoMark^TM^Japanese healthy non-pregnant women113 ± 3225[@bib22] Gas-liquid chromatography (GLC)\[49--197\]Japan pregnant women at 36 weeks gestation62 ± 28543\[6--118\]Japan women on 5th day of puerperium66 ± 23543\[20--112\]Japan women on 30th day of puerperium87 ± 21543\[45--129\]Japan pregnant Women at \>24 weeks of gestation128 (IQR 102--160)UK Normoglycemic women with glycosuric pregnancy (\~31 weeks)4616[@bib23] High-performance liquid chromatography (HPLC)(IQR 30--56)UK Normoglycemic women without glucosuric pregnancy (\~31 weeks)7216(IQR 55--79)UK Normoglycemic women (\~31 weeks)55 (IQR 31--72)32Chinese pregnant women (16--45 years) at 26--28 weeks of gestation133.0 ± 52.944[@bib24] Enzymatic pyranose oxidase\[27.2--238.8\][^8][^9]

We studied healthy Euro-Brazilian subjects, classified as children (0--14 years old), adolescent (\>14 and \<18 years old) and adults (≥18 years old). Additionally, we analyzed pregnant women in four gestational periods, \<23 weeks; 24--28 weeks, 29--32 weeks and \>32 weeks of gestation. 1,5-AG was measure by enzymatic colorimetric method (Glycomark^TM^; Tomen America, New York, NY, USA) in automated system Labmax 400 analyzer (Labtest Diagnostic).

The laboratory parameters, markers for kidney function (urea), nourishment (total protein) and lipid profile were compatible with healthy subjects ([Table 1](#t0005){ref-type="table"}).

The correlation in healthy subjects between 1,5-AG and glycemia, HbA1c, age, BMI and creatinine were weak or none ([Table 2](#t0010){ref-type="table"}).

2. Experimental design, materials and methods {#s0010}
=============================================

2.1. Study population {#s0015}
---------------------

The population comprises 2303 unrelated Euro-Brazilian healthy subjects from Curitiba, State of Parana, South of Brazil [@bib1]. All samples were obtained with the approval of the Ethics Committee of the Federal University of Parana.

Adult samples (*n* = 922) were collected from blood bank donors. Children (*n* = 580) and adolescent samples (*n* = 496) were obtained from Public Schools. Healthy pregnant women (*n* = 305) samples were obtained from the Curitiba Government Laboratory.

The normoglycemic criteria applied for selected subjects in the study were fasting glycemia \<5.5 mmol/L with an HbA1c range of 20.2--36.6 mmol/mol (4.0--5.7%) for children, adolescents, and adults. For pregnant women a fasting blood glucose \<5.1 mmol/L was applied to exclude gestational diabetes.

All subjects declared that were not using any medications or drugs.

2.2. Samples {#s0020}
------------

Samples were serum obtained in non-fasting state for adults, children and adolescents, and fasting for those who were pregnant. Blood were collected in BD vacutainers SST II advance vacutainer with silica clot activator/gel (Becton Dickinson Co.). Bloods were separated in less than two hours from venipuncture and the serum stored in an ultrafreezer (−80 °C).

2.3. Analytical methods {#s0025}
-----------------------

Concentrations of 1,5-AG were measured enzymatically with the Glycomark reagent (GlycoMark, Tomen America, New York, NY Inc.) in an automated system (Labmax 400 analyzer; Labtest. Diagnostics). The reaction details and methodology performance were described in Nowatzkea et al. [@bib6].

2.4. Clinical and laboratory parameters {#s0030}
---------------------------------------

Clinical data acquisition and analytical procedures, for laboratory data, have been reported previously [@bib2].

2.5. Data analysis {#s0035}
------------------

Descriptive statistics, correlation analysis and reference intervals were calculated with MedCalc MedCalc version 17.6 (MedCalc Statistical Software bvba, Ostend, Belgium). Probability values (*p*-values) less than 5% (*p* \< 0.05) were considered significant for all tests.
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[^1]: Values are median (25--75%; interquartile range); M, male and F, female

[^2]: HDL-c, high density lipoprotein-cholesterol; LDL-c, low density lipoprotein-cholesterol

[^3]: Abbreviations: BMI, Body mass index; n, sample size.

[^4]: NS, non-significant; --, data no available.

[^5]: Y, years old.

[^6]: US, Americans from United States; UK, English; n, sample size.

[^7]: Values were reference interval (2.5th--97.5th); \[95% calculated as mean±2--SD\]; mean±SD or median (IQR, interquartile range, 25--75%).

[^8]: US, Americans from United States; UK, English; n, sample size.

[^9]: Values were reference interval (2.5th--97.5th); \[95% calculated as mean±2−SD\]; mean±SD or median (IQR, interquartile range, 25--75%).
